EVE Health and TeleDocs to launch online prescription service for erectile dysfunction and period pain treatments

EVE Health Group’s (ASX: EVE) wholly-owned subsidiary Nextract has signed an agreement with TeleDocs Clinic & Consulting for the online prescription and promotion of its lead pharmaceutical products for erectile dysfunction (ED) and dysmenorrhoea (period pain).

The two-year agreement sees TeleDocs become the first online clinic and telehealth provider authorised to prescribe Libbo+ oral soluble film and Dyspro gummies to patients across Australia.

Both products are undergoing final-stage formulation and stability testing – a mandatory requirement under pharmaceutical product research and development guidelines – and Nextract expects to make regulatory submissions and commence manufacture before year end.

Product awareness

Under the terms of the agreement, TeleDocs has also committed to actively supporting health education and product awareness via its network of over 3,500 pharmacies nationwide.

This will include providing tools for practitioners and pharmacies, listing the new products onto major prescribing software platforms and offering national exposure via newsletters and professional education databases.

Additional initiatives include assisting in the development of practitioner- and pharmacy-facing support tools, the nationwide digital integration of new products into prescribing software and listing the products on national education platforms.

Launch plans

EVE executive director Stuart Gunzburg said the TeleDocs deal would strengthen the company’s launch plans for Libbo+ and Dyspro ahead of regulatory approvals.

“TeleDocs Clinic has deep digital health expertise, a trusted prescribing platform and a national footprint—all of which are critical to launching a new value proposition at scale, where there is an unmet clinical need,” he said.

“This agreement strengthens our commercial readiness and ensures patients can access treatment easily and safely through trusted healthcare channels.”

Nextract takeover

EVE has completed the $3 million takeover of biotech company Nextract as part of a strategic move to transition from a natural wellness brand into a broader health platform targeting regulated markets.

The acquisition positions EVE to expand into the pharmaceutical and nutraceutical sectors through Nextract’s proprietary oral delivery systems and solubility-enhancing technologies.

Specifically, it will allow the company to tap into the global ED and dysmenorrhoea markets — valued at approximately US$5.3 billion and US$10.9b respectively — that Nextract is aiming to disrupt with its lead products.